5 results
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
2 May 24
Lexicon Pharmaceuticals Reports First Quarter 2024
4:07pm
for LX9211 become the first new, non-opioid drug approved for neuropathic pain in over two decades.”
“Finally, our Genome5000™ gene knockout drug … to become the first new, non-opioid drug therapy approved in neuropathic pain in more than 20 years. Topline data from the PROGRESS study
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
, non-opioid drug approved for neuropathic pain in over two decades.”
“We are preparing for Phase 3 development of sotagliflozin in hypertrophic … initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy approved
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
8 Nov 23
Lexicon Pharmaceuticals Reports Third Quarter 2023
7:22am
profile of LX9211 and believe it could become the first new, non-opioid drug for neuropathic pain in over two decades – an area where new treatment options
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
3 Aug 23
Lexicon Pharmaceuticals Reports Second Quarter 2023
4:08pm
presented LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy: Results from a Randomized, Double-Blind
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
30 Jul 20
Lexicon Pharmaceuticals Enters into Agreement
7:18am
Therapeutics acquires, develops and markets specialty pharmaceutical products with a focus on oncology and non-opioid pain. Its mission is to provide products
- Prev
- 1
- Next